Tumor Derived Activated Cells (TDACs) refer to a specific population of cells that are derived from tumors and become activated within the tumor microenvironment. These cells play a crucial role in tumor progression, metastasis, and immune evasion.
TDACs are typically non-malignant cells that originate from various sources, such as fibroblasts, endothelial cells, macrophages, or other immune cells. However, upon exposure to the tumor microenvironment, these cells undergo activation, leading to functional changes in their behavior and properties.
Activated TDACs exhibit altered gene expression, phenotypic changes, and cellular functions that promote tumor growth and survival. These cells contribute to the remodeling of the extracellular matrix, angiogenesis (formation of new blood vessels), and suppression of anti-tumor immune responses.
Furthermore, TDACs promote the recruitment and activation of other immune cells, such as tumor-associated macrophages and regulatory T cells, which further enhance tumor growth and impair anti-tumor immune responses.
The presence of TDACs within a tumor is often associated with poor prognosis and treatment resistance. Therefore, targeting TDACs has emerged as a promising therapeutic strategy to improve cancer treatment outcomes.
In summary, TDACs are non-malignant cells originating from tumors that undergo activation within the tumor microenvironment, subsequently promoting tumor growth, invasion, and immune evasion. Understanding the mechanisms behind their activation and targeting these cells may have significant implications in cancer therapy.
